Utama › Neuroblastoma › North Carolina
Kajian klinikal Neuroblastoma di North Carolina
7 kajian untuk Neuroblastoma sedang mencari peserta di lokasi di North Carolina.
Bandar di North Carolina
Teks kajian rasmi (Bahasa Inggeris)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- dan 4 lagi
Mengambil pesertaFasa 3
Sehingga umur 30 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06172296Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Levine Children's Hospital, Charlotte
Mengambil pesertaFasa 2
Sehingga umur 22 · Semua jantina · Dikemas kini 4 Sep 2026 · NCT02559778Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
- Duke University, Durham
Mengambil pesertaFasa 2
Umur 1 hingga 21 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06540963Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- dan 3 lagi
Mengambil pesertaFasa 3
365 Days – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT03126916Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- Levine Children's Hospital, Charlotte
- Duke University, Durham
Mengambil pesertaFasa 2
12 Months – 21 Years · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT05489887SPEARHEAD-3 Pediatric Study
- Duke University School of Medicine, Durham
Mengambil pesertaFasa 1/2
Umur 2 hingga 21 · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT05642455Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Mengambil pesertaFasa 1
18 Months · Semua jantina · Dikemas kini 27 Mac 2026 · NCT03721068Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.